BioMarin Pharmaceutical Inc. Follows Genzyme Corporation's Playbook

If Jean-Jacques Bienaimé has his way, he will remake biotech company BioMarin Pharmaceutical into another Genzyme. He's got a long way to go to reach Genzyme's $2.2 billion in revenue and nearly $18 billion market capitalization, but Bienaimé looks to be on the right path with this little-known company, some investors say.

Back to news